Clinical Trial Update: TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial update on TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplantation for malignant and non-malignant disorders; study terminated wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allogeneic Hematopoietic Cell Transplantation Indications
• Malignant Disorders
• Non-malignant Disorders

Drugs mentioned

• TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplantation (TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplantation)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Allogeneic Hematopoietic Cell Transplantation | Phase 2 | Status: TERMINATED | Results posted: 2023-09-08